Fumarate treatment in progressive forms of multiple sclerosis: first results of a single-center observational study

Disease-modifying treatments for progressive multiple sclerosis

(2013) Giancarlo Comi   Multiple Sclerosis Journal

Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis

(2012) Robert J. Fox et al.   NEW ENGLAND JOURNAL OF MEDICINE

Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis

(2012) Ralf Gold et al.   NEW ENGLAND JOURNAL OF MEDICINE

Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway

(2011) Ralf A. Linker et al.   BRAIN

Efficacy of Fumaric Acid Esters in the R6/2 and YAC128 Models of Huntington's Disease

(2011) Gisa Ellrichmann et al.   PLoS One

Pharmacological management of symptoms in multiple sclerosis: current approaches and future directions

(2010) Alan J Thompson et al.   LANCET NEUROLOGY

The changing demographic pattern of multiple sclerosis epidemiology

(2010) Nils Koch-Henriksen et al.   LANCET NEUROLOGY

Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial

(2009) Kathleen Hawker et al.   ANNALS OF NEUROLOGY

A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis

(2009) X. Montalban et al.   Multiple Sclerosis Journal

The Absence of the Pro-antioxidant Transcription Factor Nrf2 Exacerbates Experimental Autoimmune Encephalomyelitis

(2009) Delinda A. Johnson et al.   TOXICOLOGICAL SCIENCES